Table 1 Patient demographics stratified into five subgroups.

From: Use of high frequency oscillatory ventilator in neonates with respiratory failure: the clinical practice in Taiwan and early multimodal outcome prediction

Variable

Term and late-preterm infants with acute respiratory failure

Rescue therapy for premature infants

Elective use of HFOV

Air leak

Patients with secondary pulmonary hypertension

No. of patients (%)

161 (14.3)

507 (45.1)

306 (27.2)

98 (8.7)

53 (4.7)

Gestational age (wks)

37.0 (34.6–38.4)

27.0 (25.0–29.0)

26.6 (25.3–28.5)

30.0 (26.4–36.4)

27.1 (25.1-29.0)

Birth body weight (g)

2785 (2410–3100)

855 (680–1150)

845.5 (703–1060)

1222.5 (832–2628.5)

846 (695–1057)

Gender (male/female)

108(67.1)/53(32.9)

288(56.8)/219(43.2)

183(59.8)/123(40.2)

66(67.3)/32(32.7)

36(67.9)/17(32.1)

Apgar score

At 1 min

7.0 (5.0–8.0)

4.0 (3.0–6.0)

5.0 (3.0–7.0)

6.0 (3.0–8.0)

5.0 (3.0–6.5)

At 5 min

9.0 (7.0–9.0)

7.0 (5.0–8.0)

7.0 (6.0–8.0)

8.0 (6.0–9.0)

7.0 (6.0–8.0)

Main respiratory disease*

RDS

65 (40.4)

375 (74.0)

239 (78.1)

50 (51.0)

0 (0)

PPHN

77 (47.8)

83 (16.4)

14 (4.6)

24 (24.5)

7 (13.2)

MAS

23 (14.3)

3 (0.2)

3 (1.0)

6 (6.1)

0 (0)

Pneumonia

12 (7.5)

11 (2.2)

5 (1.6)

0 (0)

3 (5.7)

CDH

9 (5.6)

7 (1.4)

2 (0.7)

1 (1.0)

0 (0)

Sepsis

28 (17.4)

99 (19.5)

29 (9.5)

6 (6.1)

31 (58.5)

Pneumothorax

3 (1.9)

15 (3.0)

8 (2.6)

79 (80.6)

1 (1.9)

Secondary PH

1 (0.6)

2 (0.4)

0 (0)

0 (0)

53 (100)

Pul. hemorrhage

16 (9.9)

60 (11.8)

11 (3.6)

8 (8.2)

3 (5.7)

BPD

2 (1.2)

14 (2.8)

17 (5.6)

2 (2.0)

53 (100)

PDA

85 (52.8)

229 (45.2)

152 (49.7)

30 (30.6)

4 (7.6)

IVH (≥grade III)

6 (3.7)

53 (10.5)

20 (6.5)

4 (4.1)

2 (3.8)

Hydrops Fetalis

11 (6.8)

7 (1.4)

1 (0.3)

6 (6.1)

1 (1.9)

Congenital anomalies#

8 (5.0)

3 (0.6)

1 (0.3)

1 (1.0)

2 (3.8)

Congenital heart disease

13 (8.1)

12 (2.4)

0 (0)

0 (0)

0 (0)

  1. Data are presented as number (percentage) or median (interquartile range).
  2. *Indicates concurrent respiratory diseases and disease entities which occurred at initiation of HFOV treatment.
  3. #Includes esophageal atresia with tracheo-esophageal fistula (7), cleft palate (3), Pierre Robin syndrome (1), pulmonary sequestration (4).
  4. RDS: respiratory distress syndrome; PPHN: persistent pulmonary hypertension of newborn; MAS: meconium aspiration syndrome; CDH: congenital diaphragmatic hernia; Secondary PH: secondary pulmonary hypertension; BPD: bronchopulmonary dysplasia; PDA: patent ductus arteriosus; IVH: intraventricular hemorrhage.
Back to article page